IGF1 and acromegaly: The increased IGF-1 concentration at this time point cannot be explained only by within-subject variability in IGF-1 levels [31, 32], as patients were included in the study at different time points (from October 2018 to December 2019).This observation requires further real-life studies on larger groups of patients to see if the problem of tachyphylaxis exists during treatment with pasireotide-LAR of acromegaly patients.